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Abstract 
 
Ever since the introduction of highly active antiretroviral therapy (HAART), body profile 
changes and metabolic anomalies have increasingly been witnessed in HIV-positive 
patients. Lipodystrophy which is characterized by lipoatrophy and lipohypertrophy is one 
of the most noticeable conditions. The aim of this study was to determine the possible 
association of ApoCIII, beta-3 adrenergic receptor and TNF-alpha gene polymorphisms 
with the presence of lipodystrophy in the HIV positive subjects on HAART.  
HIV-positive subjects (n= 209) were recruited from Helen Joseph Hospital and Charlotte 
Maxeke Johannesburg Academic Hospital. Control group of HIV-negative subjects 
(n=100) were also recruited for the study. Lipodystrophy was identified through patient 
self-assessments on changes in body fat using a questionnaire. Anthropometric data 
was recorded and genomic DNA extracted. A PCR-based RFLP technique was used to 
screen for ApoCIII (-T455C and -C482T), beta-3 adrenegic (-T64A) and TNF-alpha (-
G238A and -G308A) gene polymorphisms.  
Lipodystrophy was detected in 27% of the HIV positive subjects and was characterized 
by lower mean weight (62.5 ± 11.1) compared to subjects without lipodystrophy (67.6 ± 
12.9; p<0.05).The frequency for the TNF-alpha variant allele, –308A was significantly 
higher in individuals with lipodystrophy (25%) compared to those without lipodystrophy 
(13%; p<0.05). The allele frequencies for the ApoCIII, beta-3 adrenergic receptor and 
TNF alpha -238 polymorphisms were similar between patients with and without 
lipodystrophy.  Lipodystrophy in this patient cohort is characterized by lipoatrophy and 
the presence of the variant A allele at the TNF alpha -308 locus.  
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1.1 Introduction 
In 2013 it was estimated that the Human Immunodeficiency Virus (HIV) had infected                 
approximately 35 million people worldwide (UNAIDS Gap Report 2014). Since the 
introduction of Highly Active Antiretroviral Therapy (HAART) life expectancy of HIV 
infected individuals has increased; however, a number of other complications have 
developed in its wake. One of the complications that has been described is Acquired 
Immune Deficiency Syndrome (AIDS) related metabolic syndrome, specifically 
lipodystrophy (Crum et al., 2006). 
HIV/AIDS associated lipodystrophy is defined as the “redistribution” of body fat, which is 
characterized by loss of fat in the extremities and facial areas (known as lipoatrophy) 
and/or accumulation of fat in the neck and abdomen (defined as lipohypertrophy) 
(James et al., 2006).  
It has been shown that there are several factors, including dietary and metabolic, that 
may contribute to the development of lipodystrophy. Furthermore, genetic factors have 
been described to play a role in lipid metabolism including genes expressing 
Apolipoprotein C-III, βeta-3 Adrenergic Receptor and Tumour Necrosis Factor alpha 
genes. In addition, polymorphisms within these genes have been strongly linked with 
the development of lipodystrophy (Joy et al., 2008).  
However, these gene polymorphism associations have not been studied in the South 
African HIV positive population. Furthermore, the rise in life expectancy of individuals 
with HIV on HAART makes the possible effect of lipodystrophy on the quality of life 
significant for further exploration (Mallon, 2007).  
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1.2  HIV/AIDS in South Africa 
The Republic of South Africa had the highest number of people living with HIV and 
AIDS (an estimated 6.3 million) compared to any other country in 2013, (UNAIDS, 
2013). 
The Actuarial Society of South Africa released a model in 2005, shown in Table 1.1, 
which assisted in the estimation of AIDS infection, mortality and a variety of other 
indicators. This mathematical model was developed by the Actuarial Society of South 
Africa to assist the medical profession in assessing and addressing the impact of the 
HIV and AIDS epidemic in South Africa. 
Table 1.1: AIDS infection and mortality projection model 
 
http://aids.actuarialsociety.org.za/Models-3145.htm 
https://en.wikipedia.org/wiki/Actuarial_Society_of_South_Africa_HIV/AIDS_models 
 
1.3  HIV treatment: Antiretroviral therapy 
The availability of effective anti-retroviral (ARV) therapy, while incapable of curing the 
disease, has led to an improved life expectancy and has credibly been proved to reduce 
mortality (Behrens et al., 2000).  
 
Calendar Year 
starting 1 July 
 
 
2006 
 
 
2007 
 
 
2010 
 
 
2015 
Total population 47,866,985 48,218,209 49,147,178 50,328,901 
Total HIV infections 5,372,474 5,511,749 5,813,088 6,027,508 
Total AIDS sick  599,298 633,931 701,508 797,003 
Adults on ART 200,457 313,420 709,021 1,126,299 
Children on ART 25,318 38,069 81,980 111,168 
Total population 11.20% 11.40% 11.80% 12.00% 
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1.3.1 Antiretroviral drug class classification and modes of action 
There are currently five broad classes of ARVs being used, often in combination: 
1. Protease inhibitors (PIs) 
2. Nucleoside reverse transcriptase inhibitors (NRTIs) 
3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
4. Cell membrane fusion inhibitors 
5. Integrase inhibitors 
Protease inhibitors are believed to prevent viral replication by selectively binding to viral 
proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors 
that are necessary for the production of infectious viral particles (Rang et al., 2007). 
Both NRTIs and NNRTIs interfere with the process of RNA to DNA reverse 
transcription, but the mechanisms are entirely different. NRTIs inhibit this process by 
first being metabolized within the cells to be converted to their 5’triphosphate form, 
which then competes with the cells nucleotides for replication thereby inhibiting its DNA 
polymerization. Furthermore, NRTI’s lack the 3’-OH group that is essential for 
replication thus acts as a replication terminator. Thus, NRTIs work by competitively 
inhibiting reverse-transcriptase. NNRTIs on the other hand bind directly to the reverse 
transcriptase enzyme. They are not nucleoside analogs and are not incorporated into 
the DNA strand.  
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NNRTIs work by non-competitive inhibition, by distorting the catalytic site from attaining 
the metal-binding conformation necessary for DNA replication (Lewis et al., 2003).   
Fusion inhibitors interfere with the binding, fusion and entry of an HIV virion into a 
human cell. By blocking this step in HIV's replication cycle, such agents slow the 
progression from HIV infection to AIDS (Biswas et al., 2007) 
Integrase inhibitors are designed to block the action of integrase, a viral enzyme that 
inserts the viral genome into the DNA of the host cell. Since integration is a vital step in 
retroviral replication, blocking it can halt further spread of the virus (Steigbigel et al., 
2008). 
Highly Active Antiretroviral Therapy (HAART) is known as the most effective treatment 
for HIV and AIDS that combines protease inhibitors with reverse transcriptase inhibitors. 
Treatment with HAART reduces viral replication and the advancement to AIDS without 
eliminating the virus. The treatment objective with HAART is to maintain plasma viral 
load levels to < 50 copies/ml on a ultra-sensitive viral load assays (Justesen, 2006).  
In the event that a patient develops resistance due to previous ARV exposure, another 
class of medication can be added (Miller et al., 2002). Therefore, to reduce the 
likelihood of resistance due to a viral strain to all the prescribed ARVs, the treatment 
plan must include drugs with diverse resistance profiles. Furthermore, rigorous patient 
adherence to the ARV cocktail is crucial in avoiding viral resistance to the selected 
HAART regimen (Bekker and Wood, 2011). 
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       1.3.2 Effectiveness of HAART 
One of the indicators to clinical treatment response is a decrease in the viral load with a 
concomitant rise in the CD4 count. If a patient adheres to the treatment regimen and 
there is suppression of viral load, drug resistance is lowered and treatment may be 
considered successful. However, a short duration of non-adherence to HAART, even if 
the patient had been on the treatment regimen for more than two years, will lead to a 
rapid rise in the viral load (Schulenburg and Le Roux, 2008). 
In South Africa, the standardized national eligibility criteria for starting ART regimens for 
adults and adolescents is as follows (The South African Antiretroviral Treatment 
Guidelines, 2013); 
1. Eligible to start ART 
 CD4 count ≤350 cells/mm3 irrespective of World Health Organisation clinical 
stage (WHO, 2007) 
                                          OR 
 Irrespective of CD4 count 
                           - All types of Tuberculosis (TB) (In patients with TB/HIV drug resistant 
                             or sensitive TB, including extra pulmonary TB) 
                           - HIV positive women who are pregnant or breast feeding 
                                                                     OR 
                           - Patients with Cryptococcus meningitis or TB meningitis  
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 WHO stage 3 or 4 irrespective of CD4 count 
- WHO stage 3 is categorized by the following clinical manifestations, 
weight loss of greater than 10 percent of total body weight, prolonged 
(more than 1 month) unexplained diarrhoea, pulmonary tuberculosis, and 
severe systemic bacterial infections.   
(http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf) 
- The WHO clinical stage 4 (the severely symptomatic stage) designation 
includes all of the AIDS-defining illnesses. Clinical manifestations for stage 
4 disease that allow presumptive diagnosis of AIDS to be made based on 
clinical findings alone are HIV wasting syndrome, Pneumocystis 
pneumonia (PCP), recurrent severe or radiological bacterial pneumonia, 
extrapulmonary tuberculosis, HIV encephalopathy, CNS toxoplasmosis, 
chronic (more than 1 month) or orolabial herpes simplex infection, 
esophageal candidiasis, and Kaposi’s sarcoma 
(http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf) 
 
2. Require fast track (i.e. ART initiation within 7 days of being eligible) 
 HIV positive women who are pregnant or breast feeding 
                                   OR 
 Patients with low CD4 count <200 cells/mm3 
                                   OR 
 Patients with WHO Stage 4, irrespective of CD4 count 
                                  OR 
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 Patients with TB/HIV co-morbidity with CD4 count < 50  cells/mm3  
3. Patients with CD4 count above 350 cells/mm3, not yet eligible for ART 
 Transfer to a wellness programme for regular follow-up and repeat CD4 
testing 6-monthly. 
 Advise on how to avoid HIV transmission to sexual partners and children 
 Initiate INH prophylaxis if asymptomatic for TB 
 Provide counselling on nutrition and contraceptive use and perform annual 
pap smear 
The introduction of HAART has not been without side effects and lipodystrophy has 
been shown to be associated with the use of HAART. 
 
1.4. Physical and Metabolic changes in HIV positive patients on HAART   
   1.4.1 Body Composition 
Before the availability of HAART, the progression of HIV infection was often 
accompanied by body weight loss (Grinspoon et al., 2003). In its most severe form, loss 
of body weight results in HIV wasting syndrome, which is recognized as one of the 
AIDS-defining conditions (Robinson, 2004). The syndrome characterized by the loss of 
both fat mass and lean body mass is known as the wasting syndrome and is distinctly 
different from lipodystrophy, which may be characterized by changes in body fat 
distribution (Jain et al., 2012).  
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1.4.2. HIV associated lipodystrophy 
Lipodystrophy has broadly been classified as lipoatrophy and lipohypertrophy. 
Lipoatrophy is characterized by wasting of fat in the extremities and includes 
subcutaneous fat loss of the arms, legs, face and buttocks (Bonfanti et al., 2007), 
whereas lipohypertrophy is an ART linked adverse event which is characterized by fat 
accumulation in visceral areas and includes breast enlargement, buffalo hump, increase 
in neck circumference, dorsocervical fat accumulation and non-specific lipomatous 
growth (Safrin et al., 1999). The increase in visceral circumference may be as a result of 
increased intra-abdominal fat. It is also known that lipohypertrophy promotes insulin 
resistance and has been documented to occur considerably earlier than lipoatrophy 
irrespective of the site.  
Women have been shown to have a higher tendency to develop lipohypertrophy. 
Although the exact mechanism for the development of lipohypertrophy is not clear, the 
prolonged use of PIs has been implicated (Norris and Dreher, 2004). 
Interestingly, the use of NRTIs, such as stavudine (d4T) and zidovudine (AZT), have 
been associated with lipoatrophy. Although in some of the middle to low income 
countries d4T has only recently been phased out, but AZT is still widely being used. 
(Abrahams et al. 2014). 
 
The key clinical features of lipoatrophy involve the loss of subcutaneous adipose tissue 
from the face and extremities resulting in an overly muscular appearance with 
prominent veins and sunken facial features. In conjunction with the loss of peripheral 
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adipose tissue, patients also have excess accumulation of adipose tissue in the dorso-
cervical spine (buffalo hump), intra-abdominal region and around the neck area (double 
chin) (Riddler et al., 2003).  
 
Lipodystrophy is defined as the loss of subcutaneous fat and accumulation of intra-
abdominal fat (Lichtenstein et al., 2001). Assessing the physical bodily composition is 
fairly complex and the characterization of lipodystrophy may require either abdominal 
CT scan, DEXA scan, anion gap in blood and measurement of serum lipids. These tests 
and scans may reach only 80% specificity and 79% sensitivity in identifying 
lipodystrophy (De Waal et al., 2013). A simpler method of assessing lipodystrophy 
which employs a self-assessing questionnaire based on body image giving reliable 
results has been described by Asensi et.al., 2006. (used in this study).  
 
Although the physical changes observed are often associated with successful reduction 
of viral burden and elevated CD4 counts, they also carry a social stigma by presenting 
an outward sign of a patient’s HIV status. Therefore, the appearance-related side 
effects have a profound psychological effect, such as anxiety, depression and low-self- 
esteem, on patients and have been shown to impact long-term compliance to treatment 
(Chironi et al., 2003, Power et al., 2003, Asztalos et al., 2006). 
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HIV/HAART associated dyslipidemic lipodystrophy (HADL) is used to describe a 
complex assembly of physical and metabolic abnormalities directly associated with the 
use of HAART in the treatment of HIV infection (Puro et al., 2000). Frequently, HADL is 
indicated when HIV patients present with a combination of the following: elevated total 
cholesterol (> 11.0 mmol/L) combined with a decrease in high density lipoprotein (HDL) 
(<1.0 mmol/L) levels, increased triglycerides (> 1.7 mmol/L), insulin resistance and 
changes in body fat distribution with increased truncal obesity (fat accumulating around 
the abdomen and torso area) (Haerter et al., 2004). It is the manifestation of HADL 
metabolic symptoms that are considered to be significant risk factors for emerging 
cardiovascular disease (Martinez et al., 2001).  
 
Multivariate analysis has shown that lipodystrophy and HAART to be independent risk 
factors for increased intima-media thickness (Mercie et al., 2003), resulting in an 
increased risk of atherosclerosis and coronary artery disease in HIV infected patients.  
 
Associations between the use of HAART and the increased risk of cardiac events have 
been shown in a number of studies, however these associations have not been 
consistently observed. Data from studies of a large cohort type vary on the risk of 
cardiovascular events in patients treated with HAART. On a follow-up of 36 766 persons 
infected with HIV, the Veterans Affairs Cohort observed that there was a decrease in 
the amount of hospital admission for cardio- or cerebrovascular disease, related to the 
introduction of HAART (Bozzette et al., 2001). These patients however had been on a 
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combination of antiretroviral therapy for a fairly short duration: the NRTIs median time of 
exposure was for 17 months, 16 months for PIs and 9 months for NNRTIs (Bozzette et 
al., 2001). The occurrence of myocardial infarction in the HOPS cohort (HIV Outpatient 
Study) increased significantly after PIs were introduced and the use of PIs were strongly 
linked with the probability of having a myocardial infarction (Holmberg et al., 2002).  
 
1.4.3 Clinical and Metabolic characteristics of HIV Associated Lipodystrophy (HAL) 
As the use of HAART increased, reports of HAART associated lipodystrophy, thinning of 
the thighs and buttocks, buffalo humps and hypertrophy of breasts were observed 
(Stone et al., 1999) followed by reports of lipoatrophy of the face and accumulation of 
fat in the intra-abdominal (Gerrior et al., 2001). Currently, HAL is characterized by these 
features. It is not only the physical, but metabolic disorders such as insulin resistance 
and hyperlipidemia have been described to be associated with patients with HAL 
(Grinspoon, 2003). In addition to the physical changes, metabolic disoreders such as 
hyperlipidaemia and insulin resistance have been associated with HAL. 
 
1.4.4 HAART-associated Hyperlipidaemia and insulin resistance in HIV positive 
patients. 
The advent of HAART has indeed modified the natural history and progression of 
patients infected with HIV. Abnormalities in the lipid metabolism are common in HIV 
infected patients but tend to be exaggerated in those receiving HAART.  Although 
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metabolic effects of HIV infection such as increased serum triglyceride levels has been 
well documented in HAART naïve patients, studies have shown that the pattern of 
serum lipid profile changes following HAART (Singh et al., 2014); total cholesterol, 
triglyceride and low density lipoprotein levels increase following HAART initiation. It is 
thus consistent with the cardio-metabolic risk profile that defines hyperlipidaemia under 
normal conditions. However, interestingly the study also showed that there was a 
significant increase in high density lipoprotein (HDL) levels with the use of HAART. HDL 
is known as the good component in total cholesterol because of its role in reverse 
cholesterol transport. Whereas the role of LDL is to transport excess cholesterol and 
triglycerides from the liver to peripheral tissues, HDL transfers cholesterol from the 
peripheral tissues through to the liver for excretion as bile acids. This transport is 
accomplished through the exchange of cholesterol from cells to HDL through the 
interaction of ATP binding cassette A1 transporters (ABCA1) on cell surfaces and 
apolipoprotein-AI proteins within the HDL particle (Petit et al., 2002). Interestingly, even 
after arterial lesions have been established, increasing HDL levels have been shown to 
reduce the size and number of lesion in both mice and humans. Indicating that HDL 
levels may be more important in coronary artery disease (CAD) risk than total 
cholesterol and LDL levels (Das, 2005).  
Furthermore, patients who develop insulin resistance often progress to lipodystrophy, 
which is manifested in turn by the central redistribution of adipose tissue (Tershakovec, 
2004). 
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HIV associated with insulin resistance is indicative of the metabolic syndrome of 
diabesity (a form of diabetes that typically develops later in life and is associated with 
obesity) in other ways: increased plasminogen activator inhibitor-1 (PAI-1) levels and 
endothelial dysfunction is also evidently shown in these patients (Larranaga et al., 
2004).  
Therefore, it is not surprising that HAART associated metabolic syndrome increases 
cardiovascular risk (Sekhar et al., 2004) and perhaps may also be regulated by the 
same mechanisms as those assumed in diabesity.  
 
Interestingly, the development of insulin resistance does not occur in all patients 
infected with HIV on HAART treatment suggesting that there may be a genetic 
predisposition that requires investigation (Penzak et al., 2000). It is also possible that an 
increase in the number of HIV patients having insulin resistance will emerge due to 
HAART being readily accessible (Bonnet et al., 2004). Nevertheless, the standard 
insulin resistance syndrome treatment that integrates diabesity principle management 
through which patients respond to treatment includes PPAR agonists agents and 
metformin, that have been recommended (Hadigan et al., 2000).  
 
As treatments for insulin resistance and diabetes have been suggested and indicated, 
there are also treatments for hyperlipidaemia. Although the use of statins has been the 
standard treatment for most hyperlipidaemic patients, statins (with the exception of 
pravastatin) have been shown to have an unfavourable potential interaction with 
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HAART regimen due to them being metabolised by the hepatic cytochrome system. 
Therefore, the use of fibrates has been suggested to be more effective in treating 
dyslipidaemia in HIV patients on HAART. (Corsini et al., 2010).  
 
Although abnormalities in the metabolism of lipids during the progression of acquired 
immunodeficiency syndrome (AIDS) and HIV infection were detected earlier, before the 
initiation of new regimens based on PIs (Sellmeyer, 1996), the dyslipidaemia which was 
not related to HIV treatment presented with decreased LDL and HDL cholesterol plasma 
levels followed by an increase in triglyceride throughout the advanced stages of HIV 
disease. Such changes in the plasma lipid levels can be compared to those seen in 
chronic bacterial infections, some viruses and other parasites. These are linked to the 
elevation of the cytokine interferon-a (IFN-a) in the advanced phase of HIV infection that 
correlates with a decreased triglyceride production (Grunfeld et al., 1991).  
 
Simultaneously, tumour necrosis factor (TNF) may be involved in HIV-associated 
dyslipidaemia. Whilst HIV infection may not give rise to the levels of TNF, TNF may rise 
due to opportunistic infections in patients who have AIDS. This elevation may aggravate 
a decline in serum concentrations of HDL and LDL cholesterol. Interestingly, the plasma 
levels of interleukin-1 (IL-1) are not detectable in subjects that present with AIDS and 
are not related to an increase of triglycerides or cholesterol in the blood stream 
(Constans et al., 1994). 
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The progression of the HIV infection may be monitored through hypertriglyceridaemia 
and hypocholesterolaemia and have been included as markers, with a reduced CD4 
lymphocyte count being inversely related to both severity and frequency of 
dyslipidaemia (Grinspoon et al., 2001, Dubé and Cadden, 2011). Predominantly, a CD4 
cell count of lower than 200 lymphocytes/mm3 in patients who have a significantly 
reduced total cholesterol concentration than the HIV-negative subjects and those below 
400 lymphocytes/mm3 have significantly greater triglyceride concentration, when they 
are compared to matched HIV-negative controls (Constans et al., 1994).  
Hyperlipidaemia characterized by an increased concentration of serum total cholesterol, 
triglycerides, low density lipoprotein (LDL) cholesterol and low HDL cholesterol, occurs 
often in HIV positive patients who are on long-term antiretroviral therapy (ART) 
(Grinspoon et al., 2001).  
 
It has been well established that dyslipidemia and particularly increased LDL levels are 
a significant risk factor in the development of coronary artery disease (CAD) (Mallal et 
al., 2000). LDL particles are generated from very low density lipoproteins (VLDLs) which 
are secreted from the liver and carry excess hepatic cholesterol and triglycerides (TG) 
to peripheral organs for use as energy or for storage (Hui, 2003). 
 
Clinical reports on the prevalence of HADL are conflicting (Chene and Ducimetire, 
2003). The percentage of patients presenting with symptoms associated with 
lipodystrophy and dyslipidemia range from 20% to as high as 80%. The lack of a 
17 
 
unifying definition of HADL combined with interpretational differences in the significance 
of changes in HADL syndrome markers is a likely reason for variability in the incidence 
of HADL in HIV positive patient populations. Despite these differences, it is certain that 
long-term HIV survivors will face additional health risks and quality of life issues 
associated with HAART (Chene and Ducimetire, 2003).  
 
Antiretroviral agents have different effects on the hyperlipidaemia patterns and 
frequencies. PI induced hyperlipidaemia occurred in 47-75% of patients (Friis-Moller et 
al., 2003). The maximum risk of elevation in LDL and TG occurs with the use of d4T 
amongst the NRTIs. NNRTIs users may have elevated HDL and TG levels. After 
commencing therapy, lipid profile disturbances are seen in weeks to months of starting 
therapy (Friis-Moller et al., 2003). 
 
Plasma lipid abnormalities appear to be common in patients receiving a PI treatment 
regimen. This is besides the fact that dyslipidaemia is sometimes associated with 
stavudine, lamivudine, zidovudine or non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) (Carr and Amin, 2009). 
 
As mentioned previously, the incidence of hyperlipidaemia ranges in between 28 to 80% 
in patients receiving PI as their treatment regimen. Hypertriglyceridaemia was present in 
most cases which may be followed by the development of hyperglycaemia and 
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hypercholesterolaemia (Roberts and Volberding, 1999). They also showed the fat 
redistribution syndrome prevalence ranges from 10 to 80%. 
 
Dyslipidaemia is linked to the presence of lipodystrophy syndrome; however metabolic 
changes can also present without morphological changes that occur in patients who 
present with lipodystrophy. It has been observed that metabolic abnormalities usually 
precede the body fat redistribution (Mulligan et al., 2000).  
 
Hypertriglyceridaemia is associated with the depletion of fat or lipoatrophy, whereas fat 
lipohypertrophy syndrome or accumulation of fat is accompanied by dyslipidaemia 
(Yanovski et al., 1999). The following factors have been shown to be associated with 
hypertriglyceridaemia in several studies prior to the PI therapy initiation: heavier weight, 
male gender, older age, higher body mass index, homosexual orientation, AIDS 
diagnosis and higher levels of triglyceride with cholesterol plasma (Savès et al., 2002).  
 
However, studies show that these factors (gender, baseline lipid levels, HIV disease 
stage and weight of the body) may not be related with the incidence of 
hypertriglyceridaemia (Tsidras et al., 2000). Nevertheless, the association of increased 
cholesterol concentration has been pointed out by some of the authors, in HIV patients 
having higher numbers of CD4 cell count, age and body mass index (Mooser et al., 
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2001). Consequently, the hyperlipidaemia risk factors which are associated with PI 
treatment are still being investigated and hypothesized till today (Benson et al., 2002).  
 
Patients who are treated with ritonavir frequently appear to have a mild to moderate 
increase in the levels of cholesterol when compared to patients on indinavir (Periard et 
al., 1999). Indinavir, in a retrospective analysis was shown to be associated with a 
reduced risk of hypercholesterolaemia and hypertriglyceridaemia (Carr et al., 1998). 
However, it appears that it is the duration and dose that determines the progress of 
hyperlipidaemia throughout the administration of PIs. Serum lipid irregularities arise 
soon after commencing therapy, during the 3 to 12 months, although it may be earlier in 
subjects who are receiving the ritonavir-containing regimen (Manfredi et al., 2004).  
 
The highest frequency and severity of elevations in lipid level is associated with 
Ritonavir on its own or in combination with lopinavir or saquinavir (Currier et al., 2000). 
However there are limitations on the availability of data and it remains inadequate to 
determine the real effect of indinavir, nelfinavir, saquinavir and amprenavir on plasma 
lipid concentrations (Currier et al., 2000). 
 
Cumulative exposure of stavudine in some studies has been shown to be associated 
with hyperlipidaemia, even though the exact mechanism behind this effect on lipid 
metabolism is still being postulated (Mooser et al., 2001). Moreover, some studies have 
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shown that patients that have hyperglycaemia frequently present with 
hypertriglyceridaemia, while the progression of hypercholesterolaemia is inversely 
associated with chronic hepatitis C virus infection (Paparizos et al., 2000). 
 
 Alterations in the metabolism of lipids have been frequently reported in paediatric HIV 
infected patients receiving HAART. In this study 70% of children who were on ritonavir 
treatment were found to have hyperlipidaemia whilst only 50% of those receiving 
nelfinavir were found to have hyperlipidaemia (Fiore et al., 2000). 
 
1.5. Potentially life-threatening and serious adverse events: 
       1.5.1. Mechanism of Insulin Resistance 
The study reported by Perseghin et al. (2003) may be used to understand mechanisms 
responsible for insulin resistance, which may be related to the signaling pathway 
induced by acyl-CoA derivatives in the inhibition of insulin function. It is possible that 
excessive acyl-CoA inside the cytosol, exceeds mitochondrial acyl-CoA and 
peroxysomal degradation lead to the buildup of triglycerides in muscle and hepatocyte 
cells. This accumulation has been indicated in obesity, insulin resistance, metabolic 
syndrome and diabetes in several studies (Martins et al., 2012).  
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As reported by Myarcik et al., 2000, a strong association exists between the amount of 
fat accumulation in the liver and fat in the visceral area. Similarly, insulin resistance in 
diabetic and obese patients is related to the amount of fat intramyocellularly. This type 
of alterations leads to a condition referred to as lipotoxicity (Perseghin et al., 2003). 
 
Recent studies have shown that adipose tissue location is important, suggesting that 
there is a proportional association between visceral fat and insulin resistance as 
measured by the Homeostasis Model Assessment (HOMA). A method used to quantify 
insulin resistance and beta-cell function (Myarcik et al., 2000).  
 
In addition its effect may also be noted to its sensitivity to catecholamines and 
predisposition of free fatty acids (FFA) in the portal circulation. Whereas, subcutaneous 
fat releases lower levels of FFA with a priority towards peripheral tissues which is 
lipolysis resistant (Mulligan, 2001). 
 
As with most inflammatory processes there is an alteration in the cytokines profile in the 
lipodystrophic adipose tissue including increased levels of interleukin (IL)-6 and tumor 
necrosis factor (TNF)-alpha. These cytokines secreted by adipocytes, are thought to 
play an important role in the development of insulin resistance, which results in FFA 
fluxes and increased lipolysis which induces insulin resistance. Additionally, adipose 
tissue which is lipodystrophic has a reduced adiponectin secretion, which could in turn 
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result in decreased lipid oxidation, glucose uptake by the muscles and consequently a 
rise of glucose production by the liver (Brown et al., 2005).  
 
Therefore it is reasonable to suggest that lipodystrophic adipose tissue that is altered in 
function may aggravate insulin sensitivity and drug-induced alterations of metabolism in 
glucose. Additionally, it appears that it is possible that through this mechanism where 
protease inhibitors (PI) have a direct impact on lipid metabolism (Gougeon et al., 2004), 
may synergistically lead to the progression of metabolic disturbances.   
 
However, due to the different methods used to measure glucose levels and diagnose  of 
insulin resistance and diabetes it is difficult to compare the outcomes from different 
studies investigating the metabolism of glucose in patients with HAL. A study by 
Hadigen and colleagues, 2001, found that 35% of patients had impaired glucose 
tolerance (IGT) with HAL, and frank diabetes was observed in an additional 7%. Other 
studies have reported a 7 - 13% occurrence of diabetes measured by an OGTT, 17 - 
46% frequency of IGT and peripheral insulin resistance incidence up to 61% measured 
with the use of intravenous insulin tolerance test in patients receiving PIs (Behrens et 
al., 1999). Furthermore, in one study that consisted of a 1011 patients who were on 
ARVs were followed for 289 days, showed 16 new cases of diabetes was diagnosed, 
suggesting that the possibility of developing diabetes was considerably higher in 
patients who were receiving stavudine or indinavir (Mallal et al., 2000).  
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However, diabetes was a rare occurrence in patients infected with HIV prior to the 
introduction of HAART. The disturbance in glucose metabolism by medications, such as 
megestrol acetate, pentamidine or corticosteroids was often hypothesized in HIV 
positive patients (Domingo et al., 2005). Prior to the introduction of HAART regimen, 
patients had increased serum concentrations of triglycerides but decreased 
concentrations of total, LDL and HDL cholesterol in the advanced stages of HIV 
infection (Grufeld, 2004). 
 
Interestingly, pathways by which insulin resistance develops in HIV-infected individuals 
on HAART, with or without morphologic abnormalities, are believed to include impaired 
glucose uptake in skeletal muscle, impaired processing of pro-insulin to insulin and 
impaired beta cell function (Bodasing, 2003). 
 
Before PI containing HAART regimes, patients with HIV were found to present with no 
substantial insulin resistance and also with normal or reduced glucose levels (Bodasing, 
2003). Abnormality in homeostasis of glucose is suggested to be present in 20-60% of 
patients receiving PI therapy. These abnormalities are more likely to be present in 
lipodystrophy (Carr and Amin, 2009).  
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1.6 Assessment of HIV Lipodystrophy Syndrome (LDS) 
Due to a lack of standardization, the assessment of HIV LDS varies widely among 
researchers (Norris and Dreher, 2004). 
1.6.1 Methods for assessing HIV Lipodystrophy Syndrome 
Methods that are used in HIV LDS research studies include subjective self-reporting, 
assessment by physicians, anthropometric measurements, bioelectrical impedance 
analysis (BIA), magnetic resonance imaging (MRI), computed tomography (CT) scan 
and dual energy X-ray absorptiometry (DEXA). These methods of assessing HIV LDS 
vary widely in objectivity, methodology, accuracy, cost and standardization of 
classification. A standard, universal acceptable case definition is needed to address the 
above problems. A case definition for HIV LDS should include all clinical components 
seen in HIV LDS, link abnormalities or pathophysiologic mechanisms and strengthen 
the association between abnormalities and specific HAART used (Carr et al., 2003). 
 
1.6.1.1 Anthropometry 
Inexpensive ways of assessing morphological changes are anthropometric 
measurements e.g. skinfolds and circumferences (Norris and Dreher, 2004). 
Anthropometric measurements are easy to perform, non-invasive, readily available and 
practical to use in a clinical environment. Accurate measurements are dependent on 
proper training and standardization of techniques as well as the prediction equation that 
is used (Gerrior et al., 2001). 
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1.6.1.2 Weight 
One of the simplest anthropometric methods used in HIV positive persons is monitoring 
weight. Many HIV infected individuals experience substantial weight loss in a short 
period of time before initiation of treatment. Earlier studies supported the idea that 
weight loss in untreated AIDS patients is mostly loss of body cell mass, but later studies 
showed an equal loss of both fat and lean body mass. However, interestingly it has 
been shown that malnourished women, in contrast to men, tend to lose more fat than 
lean body mass (Maia et al., 2005). 
 
Once initiated on HAART individuals appear to regain their weight although it is mostly 
from the fat compartment. Even though body weight can be maintained throughout 
treatment on HAART, the loss of lean body mass (LBM) can still continue while visceral 
fat is accumulating (Jain et al., 2001). The manifestation of HIV wasting has changed in 
the era of HAART to body composition changes: LBM is wasted (lipoatrophy) and fat is 
centrally accumulated (lipohypertrophy), resulting in unchanged weight. The monitoring 
and interpretation of weight, in the face of HIV LDS, can thus be misleading and 
unreliable as a measure of fat-free-mass and changes in HIV infection (Gerrior et al., 
2001). 
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1.6.1.3 Waist and Hip circumferences 
Abdominal obesity is highly correlated with the increase in visceral adipose tissue mass. 
Waist circumference (WC) has been shown to be more associated with visceral adipose 
tissue mass than Waist Hip Ratio (WHR) and Body Mass Index (BMI). Waist 
Circumference measurement is a practical way of evaluating the presence of regional 
fat depots. A WC of more than 102cm for men and 88cm for women is positively 
associated with fat depots (Dong and Henricks, 2005). 
The most common sites for measuring WC are as follows: 
 Immediately below the lowest area of the ribs 
 At the narrowest waist (according to the Anthropometric Standardization Report 
Manual) 
 Midpoint between lowest rib and iliac crest (WHO guidelines) 
 Immediately above iliac crest (NIH guidelines) (Wang et al., 2003). 
 
 
1.7 Association of ApoCIII, Beta-3 adrenegic receptor and Tumour Necrosis 
Factor-alpha gene polymorphisms with HAART associated lipodstrophy. 
The development of lipodystrophy associated with genetic polymorphisms of, ApoCIII 
(Mallon, 2006), Beta 3 Adrenergic receptor (Okumura, 2003) and TNF alpha (Maher et 
al., 2002), genes, has been documented as described, however, this association has 
not been shown in the South African HIV positive population.  
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1.7.1 ApoCIII in HAART associated Lipodystrophy 
Apolipoprotein CIII (ApoCIII), an essential component of HDL and very low lipoprotein 
(VLDL), has been shown to be an important regulator of intravascular triglyceride 
metabolism, through the inhibition of lipoprotein lipase and interference with apoE 
mediated triglyceride–rich lipoprotein uptake by hepatic receptors (Onat et al, 2003).  
 
In-vitro and transgenic animal studies have demonstrated that over expression of 
apoCIII results in delayed clearance of triglyceride rich lipoproteins from plasma 
resulting in overt hypertriglyceridaemia. Furthermore, results of clinical studies have 
specified that apoCIII levels were better predictors of risk for the progression of CAD 
than traditionally measured serum triglyceride levels (Sacks et al., 2000). Recent 
interest has focused on the possible involvement of genetic variations in genes 
regulating lipid metabolism that may be responsible for hyperlipidaemia (Hegeleet al., 
1997). 
 
Various studies have shown that hyperlipidaemia and particularly hypertriglyceridaemia 
may have a genetic predisposition, but the gene responsible for it has not yet been fully 
elucidated (Talmud et al., 2007). Olivieri and coworkers (2003) identified an apoCIII 
polymorphism that plays a role in the metabolism of circulating triglyceride rich 
lipoproteins.  
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The human Apolipoprotien CIII (apoCIII) gene has been mapped on the long arm of 
chromosome 11 and several variant alleles have been investigated as possible genetic 
markers of hypertriglyceridaemia.  Two polymorphic nucleotides located at positions -
455 (T to C) and -482 (C to T) in the apoC-III promoter region have been identified and 
shown to influence serum triglyceride levels (Mallon, 2006). Thus, there is a great 
interest in the role of apoCIII gene polymorphism on both the expression of apoCIII as 
well as on its effects on triglyceride metabolism particularly in HAART associated 
lipodystrophy.  
 
1.7.2 Beta-3 Adrenergic receptor in HAART associated Lipodystrophy 
The beta-3-adrenergic receptor (β3AR) is found in visceral adipocytes linked to the 
receptor G-protein. In the visceral adipocytes it is involved in the regulation of 
thermogenesis and lipolysis. Stimulation of the receptor occurs by sympathetic nervous 
system activation and local secretion of norepinephrine. Enhancement of glucose 
uptake in rodent models of obesity, fat oxidation increase and energy expenditure 
improvement are pharmacological effects associated with stimulation the β3AR (Moens, 
2010).  
 
The β3AR gene is expressed in visceral fat and is a candidate gene for abdominal 
obesity. Polymorphism in the β3AR gene are closely related to insulin resistance and 
obesity of the abdomen that results in the replacement of tryptophan by arginine at 
position 64 (Trp64Arg) (Okumura, 2003). 
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To test the possibility that the development of lipodystrophy may be associated with 
β3AR polymorphism, Vonkeman and colleagues (2000) investigated this possibility. 
From a cohort that consisted of 135 HIV patients on HAART, 39 HIV patients were 
chosen: 17 without lipodystrophy and 22 with lipodystrophy.  The control group 
consisted of 200 non-HIV individuals with a body considered to be “normal” (non 
lipodystrophic). The HIV patient group with lipodystrophy having the characteristic 
features (LDS+, n=22), six patients were found to be heterozygous and none was 
homozygous for the Arg64 allele. In the HIV patients who were negative for LDS (LDS-, 
n=17) two were heterozygous, none homozygous. In the last group which were the 
control, 19 out of 200 individuals were heterozygous; one was homozygous for the 
64Arg allele.  
 
Their observation that β3AR codon mutation in the Trp64Arg is a genetic risk factor for 
peripheral lipodystrophy associated with protease-inhibitor- may be novel finding. The 
abnormalities in β3AR might lead to speculation that a reduction in lipolysis and 
thermogenesis in visceral adipocytes and thus result in the accumulation of fat in the 
abdominal region.  
 
1.7.3 Tumour Necrosis Factor-Alpha in HAART associated Lipodystrophy 
Tumour necrosis factor-alpha (TNF-α) is a multi-functional cytokine that is synthesized 
as a transmembrane monomer of 26-kDa (mTNF-α). This monomer is proteolytically 
cleaved by the TNF-α converting enzyme (TACE) to produce a soluble TNF-α molecule 
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that is 17-kD in size. Due to modulation of adipocytes differentiation and lipolysis 
adipose tissue expression of TNF-α has been implicated in lipoatrophy. The two cell 
surface receptors: tumour necrosis factor-alpha receptor 1 (TNFR1) and TNFR2 are 
used to facilitate TNF- biological effects on adipose tissue (Azmy et al., 2004). 
 
As with TNF-α, the soluble form of the receptor (sTNFR) is released from proteolytic 
cleaving of TNFRs. The major effects on the function of adipose tissue are transduced 
by a signal from TNFR 1 to mediate TNF-α as suggested by Cawthorn and Co-workers. 
Their study showed that TNFR1 is essential for the inhibition of adipogenesis through 
TNFR1 and/or TNFR2-deficient preadipocytes. However, the activity of an intrinsic 
catalytic nature is not shown by both TNFRs. Thus, it is possible that they may employ 
intracellular proteins for signal transmissions, which interrelates with specific domains of 
the cytoplasmic portions of the receptors, thereby activating specific signals 
downstream. This promotes lipolysis and adipocyte differentiation (Cawthorn et al., 
2008). 
 
 TNF-α has actions similar to those seen in lipodystrophy; therefore Maher et al (2002), 
carried out an analysis, to determine whether the presence of lipodystrophy was 
associated with the polymorphisms in the promoter region of the TNF-α gene. The         
TNF-α gene was genotyped for -238A and -308A polymorphisms in all the individuals.  
The polymorphism at position -238A in the promoter region of TNF-α has been 
associated with HAART treated patients with a likelihood of a more-rapid 
31 
 
commencement of lipoatrophy. This observation is confirmed by results in the above 
mentioned study. Therefore one can suggest that this polymorphism interferes with the 
ability of TNF-α in regulating lipolysis. 
 
Whilst high levels of cholesterol, triglyceride and insulin resistance are common features 
of ApoCIII and β3 adrenergic receptor polymorphisms, there is very sparse literature on 
the serum triglyceride and cholesterol levels associated with TNF-α polymorphism.  
 
1.8 Rationale for the study. 
Although extensive research on ApoC-III, β3AR and TNF-α in lipodystrophic patients 
has been conducted in other countries, no such studies have been done in the South 
African population. Therefore we investigated the frequency / prevalence of these 
polymorphisms in the South African HIV positive population receiving HAART.   
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Chapter 2 
Materials and Methods 
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2.1 Reagents and Chemicals 
The following reagents listed in Table 2.1 below were used. 
Table 2.1: List of Reagents 
Reagents and Chemicals Source 
Agarose Tablets 
Apo CIII Primers 
Beta-3 Adrenergic Receptor primers 
DNA (Deoxyribonucleic Acid) Extraction kit 
DMSO 
Ethidium Bromide 
Molecular Marker V 
PCR Master (Master Mix) 
PCR Loading Buffer  
Restriction Enzymes (Msp I, Fok I and  
Nco I) 
TNF-alpha and ApoCIII primers 
 
Invisorb (Invitek, USA) 
Roche Diagnostics 
Inqaba, Pretoria, South Africa 
Invisorb (Invitek, USA) 
Merck, NJ, USA 
Roche Diagnostics, Indianapolis, USA 
Roche Diagnostics, Indianapolis, USA 
Roche Diagnostics, Indianapolis, USA 
Fermentas, Johannesburg, SA 
Roche Diagnostics, Indianapolis, USA 
 
Roche Diagnostics, Indianapolis, USA 
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2.2 Collection of blood samples from subjects 
A total of 209 HIV positive subjects were recruited from Helen Joseph and Charlotte 
Maxeke Academic Hospitals. Majority of these subjects, 65%, were on 1st line treatment 
(Lamivudine, Stavudine & Efivarenz) while 33% were on 2nd line treatment (Didanosine, 
Lopinavir & Zidovudine). The remaining 2% of subjects were on the combination of 1st 
and 2nd line treatments. 100 HIV negative subjects (assumed negative by personal 
verbal confirmation) were recruited from the University of the Witwatersrand Medical 
School and Charlotte Maxeke Academic Hospital. Ethics clearance was obtained from 
the Human Research Ethics Committee of the University of the Witwatersrand and 
Informed consent was obtained from all individuals. The information was coded to 
ensure privacy and confidentiality. Twenty millilitres of blood was collected from each 
subject, 10ml of clotted blood, 5ml for blood glucose in a tube containing oxaloacetate  
and a 5ml in a tube containing EDTA (for DNA extraction).  
 
All the blood samples were centrifuged using the Beckman Centrifuge (Model TJ-6) for 
15 minutes at 2000 rpm. Serum was stored in a -20ºC freezer for lipogram, Insulin and 
Glucose tests. The buffy coat region between plasma and packed red blood cells from 
EDTA containing tubes was extracted and also stored in a -20ºC freezer for DNA 
extraction. 
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2.3 Anthropometrical Measurements    
The following anthropometric measurements were recorded; age, ethnicity, systolic and 
diastolic blood pressure, weight, hip, waist and height. Body mass index (BMI) was 
calculated by weight in kilograms (kg) divided by the square of the height in meters 
(Kg/m2). The waist circumference was measured with a soft measuring tape to the 
nearest 0,5cm at the level of the smallest girth above the umbilicus in a standing 
position. The hip circumference was measured on the widest part of the gluteus region. 
Blood pressure was measured in a sitting position by using a mercury 
sphygmomanometer with a standard cuff. 
 
2.4 Diagnosis of lipodystrophy 
Lipodystrophy in HIV positive subjects was diagnosed using a questionnaire for 
assessing body fat re-distribution in HIV-positive patients receiving HAART in Appendix 
E (Asensi et al., 2006). The face, breast, belly, arms, legs and buttocks/hips were 
assessed for body fat changes (both losses and gains). Changes were rated as absent 
(score of 0), mild (score of 1; noticeable only on close inspection), moderate (score of 2; 
easily noticeable by patient and doctor) or severe (score of 3; easily noticeable by 
casual observer). These changes were reported by the patient and confirmed by the 
clinician. The scores for each of the 7 body areas were added together to diagnose 
lipodystrophy. Furthermore subjects with scores of 3 for any individual body area were 
also diagnosed with lipodystrophy. 
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2.5 Glucose and Lipid measurements 
2.5.1 Glucose measurement 
Fasting blood glucose levels were measured in the routine chemistry laboratory (NHLS) 
in Charlotte Maxeke Hospital by a glucose oxidase method (glucose GODPAP, 
Boehringer Mannheim) using the Hitachi 717 Autoanalyser. Subjects who at the time of 
the study had already been diagnosed as diabetics, were defined as diabetics 
irrespective of the levels obtained on the day. Hyperglycaemia was defined according to 
the WHO criteria. As per the World Health Organization people with fasting glucose 
levels from 6.1 to 6.9mmol/l (110 to 125mg/dl) are considered to have impaired fasting 
glucose. Subjects with plasma glucose at or above 7.8mmol/l (140mg/dl), but not over 
11.1mmol/l (200mg/dl), two hours after a 75g oral glucose load are considered to have 
impaired glucose tolerance. Of these two pre-diabetic states, the latter in particular is a 
major risk factor for progression to full-blown diabetes mellitus, as well as 
cardiovascular disease. 
 
2.5.2 Measurement of serum lipid levels 
Lipogram measurements were done in the routine chemistry laboratory (NHLS) in 
Charlotte Maxeke Hospital using a Modular ISE 900 Autoanalyser (Roche Diagnostics, 
Mannheim, Germany). 
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LDL-cholesterol was calculated using triglyceride and cholesterol levels using the 
Friedewald formula as follows: LDL = (total cholesterol – HDL) – (triglycerides/2.22) 
(Friedwald, 1972). A value of between 4.1-4.9mmol/L was considered 
hypercholesterolaemia. 
 
2.6 DNA Extraction 
DNA (Deoxyribonucleic Acid) was extracted from the buffy coat of the blood, which is 
the leukocyte-enriched fraction of whole blood. The Invisorb spin blood mini kit (Invitek, 
USA) was used to extract DNA. The following protocol for DNA extraction was followed 
(supplied in the kit): 
The required amount of elution buffer was transferred into a 2.0ml receiver tube and the 
tube placed in a Multi-Blok heater (Thermo Scientific, SA) at 56ºC. 
- Lysis at 56 ºC for 10 min in a Thermomixer 
Two hundred microlitres of buffy coat was placed into a 1.5ml tube, to which 200µl of 
lysis buffer and 20µl proteinase k was added. The tube vortexed and incubated in a 
Thermomixer at 56ºC for 10min. 
- Realizing of optimal binding conditions   
To the lysed sample 400µl of binding buffer was added, vortexed for 2-5 seconds and 
was carefully loaded onto the spin filter and incubated for 1min at room temperature. 
The sample was then centrifuged for 2min at 12 000rpm. The receiver tube was 
38 
 
discarded with the filtrate after centrifugation. The spin filter with the sample in it was 
placed in a new 2.0ml receiver tube. 
- Washing I 
To the spin filter 500µl wash buffer I (containing ethanol) was added and centrifuged for 
1min at 12.000rpm. The filtrate was discarded and the spin filter was placed in the 2.0ml 
receiver tube. 
- Washing II  
To the spin filter 800µl wash buffer II was added and centrifuged for 1min at 12 000rpm. 
The filtrate was discarded then the spin filter was placed back into the 2.0ml receiver 
tube. To remove the wash buffer completely the receiver tube was centrifuged for 4min 
at 12 000rpm. 
- Elution of the DNA 
The spin filter was then placed into a new 1.5ml receiver tube. To the spin filter 200µl of 
prewarmed (56ºC) elution buffer was added. The tubes were then centrifuged for 1min 
at 12000rpm. The filtered product contained DNA. The DNA was stored at -20ºC before 
use.  
- DNA concentration 
The concentration of the DNA was determined using a Nanodrop ND-1000 (Nanodrop 
Technologies, USA). DNA concentration was obtained at of 260nm wavelength and the 
purity of DNA assessed using the ratio of absorbance at 240/260 - 260/280nm  was 
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used to assess the purity of DNA.  A ratio of less than 2 indicates the presence of 
protein contamination. 
 
2.7 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is a molecular technology used to amplify a 
single copy or a few copies of DNA across several orders of magnitude, generating 
thousands to millions of copies of a particular DNA sequence (Joshi et al., 2011). PCR 
consists of the following steps: 
 Initialization step: This step consists of heating the reaction to a temperature of 
94–96 °C for 1–9 minutes.  
 Denaturation step: This step is the first step of the cycling event and consists of 
heating at 94–98 °C for 30-60 seconds resulting in the denaturation of the DNA 
template by disrupting the hydrogen bonds between matching bases, creating 
single-stranded DNA molecules. 
 Annealing step: The reaction temperature is lowered to 50–65 °C for 30–60 
seconds allowing annealing of the primers to the single-stranded DNA template. 
The annealing temperature is approximately 3–5 °C below the melting 
temperature (Tm) of the primers used.  
 Extension/elongation step: The temperature at this step depends on the DNA 
polymerase used; Taq polymerase has its optimum activity temperature at      
70–75 °C and commonly a temperature of 72 °C is used for 30-60 seconds. In 
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this phase the DNA polymerase synthesizes a new DNA strand complementary 
to the DNA template.  
 Final elongation: This single step is frequently performed at a temperature of 70–
74 °C for 5–15 minutes after the last PCR cycle to ensure that any remaining 
single-stranded DNA is fully extended. 
 Final hold: This step at 4–15 °C for an unlimited time may be employed for short-
term storage of the reaction. 
PCR was done on the genomic DNA for the amplification of the specific genes (ApocIII, 
Beta-3 Adrenergic receptor & TNF Alpha) Primers specific for each gene were used 
table 2.2. 
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Table 2.2: Primer sequences for each gene 
Gene Forward primer sequence Reverse primer sequence 
ApoCIII455 5´-GGCTGTGAGACTCAGCCCT-3´ 5´-TCACACTGGAATTTCAGGCC-3´´ 
ApoCIII 482 5´-GGCTGTGAGACTCAGCCCT-3´ 5´-TCACACTGGAATTTCAGGCC-3´ 
3- ADR 5´-CAATACCGCCAACACCAGTGGG-3´ 5´-GGTCATGGTCTGGAGTCTCG-3´ 
TNF-α 238 5´- GAAGACCCCCCTCGGAACC -3´ 5´- ATCTGGAGGAAGCGGTAGTG -3´ 
TNF-α 308 5´-GCAATAGGTTTTGAGGGCCATG -3´ 5´- GGGACACACAAGCATCAAGGAT -3´ 
 
 
2.7.1 Preparation of the Master Mix 
The master mix was prepared to ensure optimised concentrations of all reagents. The 
master mix contained distilled water, buffer, magnesium chloride, dNTPs, primers and 
Taqpolymerase.  
The master mix was prepared as in Table 2.3 and DNA was added to each individual 
reaction. Primers specific for each gene were used for each master mix. A final total 
volume of 25l PCR reaction was used. 
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Table 2.3: Volume and Concentration of the PCR reaction 
 
Reagent 
 
Concentration 
 
Volume 
Water 
Master mix (Roche) containing: 
           Taq 
Mg++     
dNTP 
Forward primer 
Reverse primer 
DMSO 
Template DNA  
Total Volume 
- 
 
1 unit 
1.5 mmol 
3.2 mmol 
0.5 pmol 
0.5 pmol 
5% 
6.8 l 
12.5l 
 
 
 
0.1l 
0.1l 
0.5l 
5l 
25l 
 
2.7.2 PCR temperature cycles 
The C1000 Thermal Cycler (Biorad-Laboratories) was programmed for PCR, conditions 
for each of ApoCIII, β3AR and TNF-α is shown in tables 2.4, 2.5, 2.6 and 2.7. 
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Table 2.4:  PCR temperature conditions for ApoCIII 455 and 482 genes. 
Conditions  Temperature  Time  No. of cycles 
Denaturation  95ºC 11 minutes 1 X 
Denaturation  94ºC 45 seconds  
Annealing  60ºC 30 seconds  
Extension  72ºC 45 seconds  
Final Extension  72ºC 10 minutes 1 X 
Hold 4 ºC ∞  
 
 
Table2.5:  PCR conditions for Beta-3 adrenergic receptor gene. 
Conditions  Temperature  Time  No. of cycles 
Denaturation  95ºC 11 minutes 1X 
Denaturation  94ºC 45 seconds  
Annealing  59ºC 2:30 minutes  
Extension  72ºC 45 seconds  
Final Extension  72ºC 10 minutes 1X 
Hold 4 ºC ∞  
35 X 
30 X 
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Table 2.6: PCR conditions for TNF-α 238 gene. 
Conditions  Temperature  Time  No. of cycles 
Denaturation  95ºC 5 minutes 1X 
Denaturation  94ºC 1 minute  
Annealing  58ºC 1 minute  
Extension  72ºC 1 minute  
Final Extension  72ºC 7 minutes 1X 
Hold 4 ºC ∞  
 
Table 2.7: PCR temperature conditions for TNF-α 308 gene. 
Conditions  Temperature  Time  No. of cycles 
Denaturation  95ºC 11 minutes 1X 
Denaturation  94ºC 45 seconds  
Annealing  55ºC 30 seconds  
Extension  72ºC 45 seconds  
Final Extension  72ºC 10 minutes 1X 
Hold 4 ºC ∞  
 
35 X 
35 X 
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2.7.3 Gel electrophoresis and Single Nucleotide Polymorphism detection 
 The amplified PCR products for each gene were digested with a specific 
restriction endonuclease.  The ApoCIII 455 gene was digested with Fok I 
restriction enzyme and the ApoCIII482 with Msp I in two separate reaction tubes. 
The 3-ADRgene was digested with Msp I restriction enzyme Msp I and Nco I 
restriction enzymes were used to digest the TNF-α 238 and TNF-α 308 
respectively. The digestion sites are also shown in Table 2.8.  
 The total volume of the reaction mixture was 20l (15l of PCR product, 2l of 
buffer, 2l of water and 1l of the restriction enzyme).  
 The reaction was incubated at 37°C for 2hrs 
Table 2.8: Cut site of each restriction endonuclease 
Enzyme  Cut Site 
Fok I (Roche Diagnostics) 5´- GGA TG -3´ 
3´- CCT      AC -5´ 
Msp I (Roche Diagnostics) 5´-C  CGG-3´ 
3´-GGC   C-5´ 
NcoI (Roche Diagnostics) 5´-C  CATGG -3´ 
3´- GGTAC  C -5´ 
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 The samples were incubated for 2 hours at 37°C 
 After incubation the samples were prepared by mixing 20l mIcrolitres of PCR 
product with 2l the loading buffer and then loaded on a 2% agarose gel. 
Preparation of the loading buffer is described in Appendix A. 
 After all the samples were loaded onto the electrophoresis gel, the voltage was 
set at 100V. The gel was run for 60 minutes. 
 The resulting bands for each gene were visualized under UV light using the Bio-
Rad Gel Doc. The expected bands for each polymorphism are shown in Table 
2.9. A DNA base length Marker V (20-600bp) was included in all the gel runs and 
band lengths. 
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 Table2.9: Expected sizes of the different genotypes of each amplified product. 
Gene Band size 
(Homozygote for 
the wildtype) 
Band size 
(Heterozygote for variant) 
Band size 
(Homozygote 
for the variant) 
Fok I (ApoCIII T455C) 129 bp + 133 bp 
TT 
129 bp + 133 bp + 196 bp 
TC 
196bp             
CC 
Msp I (ApoCIII C482T) 143 bp 
CC 
143 bp + 159 bp 
CT 
159 bp 
TT 
Msp I (β3-Adr T64A) 54 bp + 99 bp 
TT 
54 bp + 70 bp + 99 bp 
TA 
54 bp+70 bp 
AA 
Msp I (TNF-α G238A) 132 bp 
GG 
132 bp + 151 bp 
GA 
151 bp 
AA 
Nco I (TNF-α G308A) 126 bp 
GG 
126 bp + 144 bp 
GA 
144 bp 
AA 
 
 The data in Table 2.9 was used to genotype an individual as a homozygous for 
the wildtype, heterozygous for variant or homozygous for variant. 
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2.8 Data Analysis 
The data was analyzed using the Statistica program (version 8; Microsoft, USA). 
Distributions of different alleles were calculated by the Hardy-Weinberg equilibrium. 
Differences in prevalence of the different alleles between population groups were 
analyzed by using the Chi-Squared test. Differences in the anthropometric variables 
between the different genotypes and ethnic groups were analyzed using one way 
analysis of variance (ANOVA) which tests the differences between the means of two or 
more groups. The metabolic and anthropometric data is expressed in tables as mean ± 
SD. 
2.8.1 Hardy-Weinberg Equilibrium (HWE) 
Hardy-Weinberg Equilibrium (HWE) is the test comparisons of the observed and 
expected genotype frequencies calculated in an observed population. A population is 
said to be in HWE for a given locus if there is random mating with respect to the locus, 
no selection, no mutation, no gene flow and a population is big enough to avoid the 
random effect of genetic drifts. If a population is not in HWE, it might be due to one 
population with selection that causes it to be out of equilibrium. This may include non-
random mating, gene selection and small population size.  
If two populations display HWE, there is a possibility that difference in allele frequencies 
between the two populations is due to reproductive isolation. To determine if the 
population is in HWE, the equation p2+2pq +q2 =1is used to determine expected 
genotype frequencies from allele frequencies where p and q represent homozygous 
allele frequencies. 
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2.8.2 Chi-Squared Goodness- of-Fit Test 
This test is used to determine whether there is a significant difference between the 
observed and expected genotype frequencies. The Chi-Square (2) is calculated by the 
following equation:  2 = (Observed-Expected)2 
                                                      Expected 
In the Chi-Square test, two hypotheses are tested. The first hypothesis is the Null 
Hypothesis (H0), which states that there is no difference due to chance between the 
observed and expected values, therefore the population is in HWE. The second 
hypothesis is called Alternative Hypothesis (Ha), which states that the observed and 
expected values are significantly different due to other reasons other than chance. Thus 
the population is not in HWE.  
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3.1 Ethnicity, Gender and HIV status classification of study participants 
Table 3.1 Subjects by ethnicity, gender and HIV status recruited for the study 
  
Africans Indians Whites 
HIV 
positive 
HIV 
negative 
HIV 
positive 
HIV 
negative 
HIV 
positive 
HIV 
negative 
Males (n) 63 19 1 - 1 - 
Females (n) 143 70 - 11 1 - 
 
3.2 Anthropometric Measurements 
The following anthropometric results were obtained from the subjects recruited in the 
study;  
Table 3.2: Anthropometric results 
  
HIV positive 
(n=209) 
HIV negative 
(n=100) 
P-value (HIV positive vs 
HIV negative) 
Males (n) (%) 65 (31%) 19 (19%) - 
Females (n) (%) 144 (69%) 81 (81%) - 
Age 39±8 36±11 <0.01** 
Weight (kg)  67.5 ±14.0 74.0 ±18.3 <0.01** 
Height (cm) 163.4 ±7.9 160.6±7.6 <0.01** 
BMI (kg/m2)  25.3 ±5.2 28.7 ±7.1 <0.01** 
Waist (cm)  85.1 ±12.7 86.4 ± 14.8 0.43 
Hip (cm)  98.5 ±12.1 106.7 ±14.2 <0.01** 
Glucose (mmol/L) 5.2 ±1.3 4.8 ±0.6 <0.01** 
Insulin (µU/mL) 16.1 ±17.4 11.0 ±8.9 <0.01** 
Triglycerides (mmol/L)  1.8 ±1.2 1.1 ±0.6 <0.01** 
Cholesterol (mmol/L) 4.6 ±1.2 4.6 ±1.0 0.81 
HOMA 3.7 ± 5.8 2.3 ±2.2 <0.01** 
HDL (mmol/L) 1.3 ±0.5 1.7 ±0.8 <0.01** 
LDL (mmol/L) 2.6 ±1.0 2.5 ±0.9 0.32 
Systolic (mmHg) 122.2 ±16.4 117.7 ±17.6   0.03** 
Diastolic (mmHg) 78.9 ±10.5 78.4 ±10.7 0.68 
Data shown as mean ±SD; **=statistically significant 
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The majority of HIV positive subjects were females with a 69% representation in this 
study. The HIV positive group had a significantly (p<0.0.5) lower weight compared to the 
control group (HIV negative). BMI (Body Mass Index) in the HIV positive group was 
significantly lower (p<0.05) in contrast to the control group. Hip measurements and 
HOMA revealed a significantly varied difference between the control and HIV positive 
group. The HIV positive group includes subjects which were both fasting and non-
fasting, a comparison of glucose, cholesterol, insulin and lipid profile measurements 
with the control group may be distorted. However a direct comparison of fasting 
samples between the subject with and without lipoatrophy shown below in table 3.3. 
 
 A lipodystrophy questionnaire was used in HIV positive subjects to identify the 
presence of lipodystrophy. The questionnaire identified 78 subjects with lipodystrophy. 
Lipoatrophy was particularly present in 21 of the 78 subjects. The anthropometric and 
biochemical results for subjects with and without lipodystrophy are shown in Table 3.3 
below. 
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Table 3.3: Anthropometric results for subjects with and without lipoatrophy 
  
HIV(+ve) with   
Lipoatrophy 
fasting (n=21) 
HIV(+ve) without   
Lipoatrophy 
fasting (n=57) 
 
P-value 
Age 42 ±8 38±7 0.05* 
Weight (kg)  62.5±11.1 67.6±12.9 0.09* 
Height (cm) 162.7±8.9 164.1±8.0 0.54* 
BMI (kg/m2)  23.7±4.5 25.1±4.6 0.23* 
Waist (cm)  82.5±9.9 85.9±11.9 0.21* 
Hip (cm)  94.6±10.4 98.2±10.7 0.18* 
Glucose (mmol/L) 5.5±1.8 4.8±0.6 0.11* 
Insulin (µU/mL) 19.0±36.6 15.3±14.2 0.68* 
Triglycerides (mmol/L)  1.9±1.3 1.9±1.6 0.92* 
Cholesterol(mmol/L) 4.7±1.4 4.7±1.1 0.90* 
Homa (Molar Units) 3.7±5.8 3.6±3.9 0.40* 
HDL(mmol/L) 1.2±0.3 1.2±0.4 0.86* 
LDL(mmol/L) 2.6±1.3 2.7±0.9 0.78* 
Systolic (mmHg) 118.0±8.5 121.1±17.1 0.28* 
Diastolic (mmHg) 76.8±5.5 76.7±12.8 0.98* 
Data shown as mean ±SD; *=statistically not significant 
 
Fasting subject’s results within the HIV positive group were used in table 3.3. Thirteen 
(62%) of HIV positive with lipoatrophy were females. As expected the weight and BMI of 
the HIV positive group with lipoatrophy was lower than the group without lipoatrophy, 
although not statistically significant. The waist and hip sizes for subjects with lipoatrophy 
was insignificantly smaller than subjects without lipoatrophy. Glucose, HOMA, 
cholesterol, triglycerides, insulin and lipid profile measurements were not significantly 
different between patients with and without lipoatrophy. 
 
 
54 
 
Table 3.4 Gender and ethnicity comparison in subjects with and without 
lipodystrophy  
  
HIV+ with   
Lipoatrophy 
fasting (n=21) 
HIV+ without   
Lipoatrophy 
fasting (n=57) 
Males (n) (%) 8 (38%) 16 (28%) 
Females (n) (%) 13 (62%) 41 (72%) 
Ethnicity 
African 20 (95%) 56 (98%) 
Indian 1 (5%) - 
White - 1 (2%) 
Data shown as actual n (%) 
The above results further indicates that females contribute the highest percentage 
(62%) in the subject group of HIV + with Lipatrophy. 
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3.3 PCR and single nucleotide polymorphism (SNPs) 
3.3.1ApoCIII T455C and C482T genotyping 
PCR products were run on 2% agarose gel to confirm amplification of DNA. Restriction 
enzyme Fok I was added into the PCR product to identify the T455C polymorphism and 
Msp I to identify the C482T polymorphism in two separate reactions.  
Figure 3.1 and 3.2 show visualized results of ApoCIII T455C and C482T under UV light 
respectively. 
 
  
Figure 3.1: Gel image of PCR products for the ApoCIII T455C polymorphism. Lane 1= 
Heterozygote for the variant TC (196bp+133bp+129bp), Lane 2= Homozygote for the 
wildtype TT (133bp+129bp), Lane 4= Homozygote for the variant CC (196bp), Lane 6= 
Undigested PCR product (Control), Lane 7= Molecular Marker V and Lane 12= Blank 
(Control). 
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Figure 3.2: Gel image of PCR products for the ApoCIII C482T polymorphism.          
Lane 2= Homozygote for the wildtype CC (143bp), Lane 6= Undigested PCR product 
(Control), Lane 7= Molecular Marker V, Lane 8= Homozygote for the variant TT 
(159bp), Lane 12= Heterozygote for the variant CT (159bp+143bp) and Lane 15= Blank 
(Control). 
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3.3.2 TNF-alpha G238A and G308A genotyping 
Restriction enzymes Msp I and Nco I were was added into the PCR product to identify 
polymorphism G238A and G308A respectively. Figure 3.3 and 3.4 show visualized 
results of TNF-alpha G238A and G308A respectively. 
 
 
 
Figure 3.3: Gel image of PCR products for the TNF-alpha G283A polymorphism 
(Digested with Msp I enzyme). Lane 2= Homozygote for the variant AA (151bp),  
Lane 6= Heterozygote for the variant GA (151bp+132bp), Lane 7= Undigested PCR 
product (Control), Lane 8= Molecular Marker V, Lane 11= Homozygote for the wiltype 
GG (132bp) and Lane 16= Blank (Control).  
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:  
 
Figure 3.4: Gel image of PCR products for the TNF-alpha G308A polymorphism 
(Digested with Nco I enzyme). Lane 1= Blank (Control), Lane 3= Heterozygote for the 
variant GA (144bp+126bp), Lane 6= Undigested PCR product (Control), Lane 7= 
Molecular Marker V, Lane 11= Homozygote for the wildtype GG (126bp) and Lane 
13=Homozygote for the variant AA (144bp). 
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3.3.3 Beta-3 Adrenergic receptor genotyping 
Restriction enzyme Msp I was added into the PCR product and incubated for two hours 
in at 37ºC. Figure 3.5 shows visualized results of Beta-3 Adrenergic receptor T64A 
under UV light. 
 
 
 
 
Figure 3.5: Gel image of PCR products for theBeta-3 Adrenergic receptor T64A 
polymorphism (Digested with Msp I enzyme). Lane 1= Homozygote for the wildtype TT 
(99bp+54bp), Lane 4= Heterozygote for the variant TA (99bp+70bp+54bp), Lane 6= 
Undigested PCR product (Control), Lane 7= Molecular Marker V, Lane 9= Homozygote 
for the variant AA (70bp+54bp) and Lane 13= Blank (Control).  
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3.4 Genotyping results 
Table 3.5 and Table 3.6 represent the frequency distribution of genotype across each 
subject group. Distribution for all the frequency polymorphisms was within the Hardy-
Weinberg Equilibrium. 
 
Table 3.5: Comparison of genotype distribution between HIV negative and HIV positive   
                 subjects. 
   
    
HIV Positive 
(n=209) 
 
HIV Negative 
(n=100) 
ApoCIII 
T455C  T= 0.26 T= 0.23 
C= 0.74 C= 0.77 
C482T  C= 0.28 C= 0.23 
T= 0.72 T= 0.77 
β3-Adrenergic 
receptor  
T64A  T= 0.88 T= 0.87 
A= 0.12 A= 0.13 
TNF alpha  
G238A  G= 0.90 G= 0.92 
A= 0.10 A= 0.08 
G308A  G= 0.83 G= 0.84 
A= 0.17 A= 0.16 
 
Genotyping results for ApoCIII, both T455C and C482T, revealed no significant allele 
frequency difference between the HIV positive and HIV negative groups. There was 
similar finding with genotyping results for the ApoCIII C482T.  
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The lipodystrophy questionnaire was used to identify subjects with and without 
lipoatrophy. Table 3.6 represents those findings across each genotype. 
 
Table 3.6: Comparison of genotype distribution between subjects with and   
                 without Lipoatrophy 
   
   With 
Lipoatrophy(n=71) 
Without 
Lipoatrophy(n=138) 
ApoCIII 
T455C  T= 0.29 T= 0.28 
C= 0.71 C= 0.72 
C482T  C= 0.25 C= 0.27 
T= 0.75 T= 0.73 
β3-Adrenergic 
receptor  
T64A  T= 0.94 T= 0.87 
A= 0.06 A= 0.13 
TNF alpha  
G238A  G= 0.94 G= 0.93 
A= 0.06 A= 0.07 
G308A  G= 0.75 G= 0.87 
A= 0.25* A= 0.13* 
*TNF-A (variant) 308: 0.25 vs 0.13; p<0.05 
 
The difference in frequency of the T and A alleles in the β3-Adrenergic receptor 
polymorphism between subject with and without lipoatrophy was not significant. The 
major finding showed that the frequency of the A allele in the TNF alpha 308 
polymorphism was significantly higher in subjects with lipoatrophy. The result suggests 
that lipoatrophy is associated with the presence of the variant allele A at the TNF alpha 
308 locus. 
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3.5 HIV treatment results 
The results of patients with and without lipoatrophy were further classified into the 
treatment type these subjects were on. The treatment duration was also considered in 
this classification. The results are represented in table 3.7.  
 
Table 3.7: Comparison of treatment duration between patients with and without   
                 Lipodystrophy 
 
Patients with 
Lipoatrophy (n=71) 
Patients without 
Lipoatrophy (n=138) 
 
P-value 
Treatment 
duration 
(months) 39 months ± 20 32 months ± 18 
 
 
0.02 
1st Line 
treatment (%) 85% (n=60) 57% (n=79) 
2nd Line 
treatment (%) 15% (n=11) 
 
43% (n=59) 
 1st Line treatment = Lamivudine, Stavudine & Efivarenz 
2nd Line treatment= Didanosine, Lopinavir & Zidovudine 
 
 
Results in table 3.7 indicate that a higher percentage (85%) of subjects with lipoatrophy 
is on the 1st line treatment of HIV. There was also a significant difference in the 
treatment duration between subjects with and without lipoatrophy. This finding indicates 
that the longer subjects are on treatment the higher the possibility of developing 
lipoatrophy.  
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Discussion 
The introduction of highly active antiretroviral therapy has been accompanied by body 
profile changes and metabolic anomalies in HIV-positive patients. Lipodystrophy is one 
of the most noticeable condition which is characterized by lipoatrophy and 
lipohypertrophy. The main objective of this study was to determine the possible 
association of ApoCIII, beta-3 adrenergic receptor and TNF-alpha gene polymorphisms 
with the presence of lipodystrophy in the South African population.  
Anthropometric Measurements 
Majority of the HIV positive subjects (n=209) recruited in this study were females (69%) 
compared to the 31% of males. HIV positive subjects had significantly lower weight 
(67.5 ±14.0 vs. 74.0 ± 18.3; p< 0.05) and BMI (25.3 ±5.2 vs 28.7 ± 7.1; p< 0.05) as 
compared to the HIV negative control subjects. Although there was no significant 
differences in the total serum cholesterol and LDL concentrations between the HIV 
positive subjects and the HIV negative control subjects, serum triglyceride 
concentrations were significantly higher in the HIV positive subjects (1.8±1.2 vs 1.1±0.6; 
p<0.05) and HDL was significantly (1.3 vs 1.7mmol/l) lower in the HIV positive group. 
There have been theories as to why lipid abnormalities occur in the HIV-infected 
population, including those implicating both the viral infection as well as the antiretroviral 
therapy (Carr et al., 1998). A number of studies have shown hyperlipidemia to be a 
complication in HIV-infected patients receiving antiretroviral therapy, especially protease 
inhibitors and stavudine. The incidence of hyperlipidemia in HIV-infected patients taking 
protease inhibitors has extended from 8% to as high as 66% (Kaul et al., 1999). 
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 In addition the glucose concentrations (5.2mmol/l vs 4.8mmol/l) in the HIV positive 
subjects was significantly (p<0.05) higher than the HIV negative subjects. Insulin 
concentrations were also significantly higher (p<0.05) in the HIV positive subjects 
(16.1µU/mL) as compared to the HIV negative subjects 11.0µU/mL), thereby indicating 
that the HIV positive subjects may be at risk of developing insulin resistance as 
indicated by a higher HOMA index of 3.7 vs 2.3 for the HIV positive subjects as 
compared to the HIV negative subjects.  
 
The HIV positive subjects were further stratified into two groups comprising of subjects 
with lipoatrophy and without lipoatrophy. The HIV positive group with lipoatrophy had an 
n number of 21(27%) whilst the group without lipoatrophy had an n of 57 (73%).                               
The anthropometric results showed that patients with lipoatrophy had a trend of lower 
weight and BMI although the difference was not statistically significant. The waist and 
hip measurements were also smaller in subjects with lipoatrophy although the difference 
was not significant. Furthermore, there was no significant difference in the biochemical 
parameters, glucose, cholesterol, triglycerides, insulin and lipogram between the two 
groups. These results were similar to the cross sectional study conducted by Innes et al. 
2012, on the high prevalence of lipoatrophy in pre-pubertal South African children on 
antiretroviral therapy that showed similar findings. In their study among 100 subjects 
that were recruited, the prevalence of visually obvious lipoatrophy was 36%. Overall, 
children with and without lipoatrophy had similar weight-for-age Z-score, height-for-age 
Z-score, gender distribution, ethnic distribution, WHO clinical stage, viral load and mean 
CD4. 
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Interestingly, although there were more female patients in the present study which could 
be viewed as a biased sampling, the results further indicated that 62% of the 21 
subjects that presented with lipoatrophy were females and 95% were of the African 
ethnicity. These results indicate that females may be at higher risk of lipoatrophy than 
males, similar results were also shown by Sorli et al.2007, who reported that women 
were at a greater risk of lipodystrophy compared to men. A plausible explanation for this 
is that females are more likely to report fat accumulation in the abdomen and breasts 
and hypertriglyceridemia, whereas men are more likely to describe fat depletion from 
the face and extremities, along with hypertension and hypercholesterolemia. 
 
Indeed there have been studies reporting on various genetic factors and polymorphisms 
implicated in the regulation of lipid metabolism and development of lipodystrophy 
including polymorphisms in, Apo CIII, Beta 3 Adrenergic receptor and TNF alpha genes. 
However, only a few studies reported on their impact on HIV and specifically on HIV 
positive patients receiving HAART. Bonnet (2004), reported elevated concentration of 
triglycerides in HIV patients having the ApoCIII polymorphisms with the frequency of .04 
for the -455C allele and 0.31 for the -482T allele. However, in the present study ApoCIII 
genotype results for both the T455C and C482T polymorphisms were not significantly 
different between the HIV positive and negative group. Furthermore, the allelic and 
genotypic frequencies at the polymorphic -482 and -455 loci of the apoCIII were similar 
to the findings by Naran et al., 2009, which was investigated in the South African 
populations. Although ApoCIII has been implicated in the development of 
hypertriglyceridaemia the results of this study indicates that the Apo CIII polymorphisms 
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may play only a limited role if any in the development of lipodystrophy and 
hypertriglyceridaemia in HIV positive subjects on HAART. A possible explanation for the 
differences between this study and that of Bonnet (2004) is that the prevalence of gene 
polymorphism have been shown to differ between different ethnic groups. 
 
Additionally, there was no significant difference in the TNF-alpha (G238A & G308A) and 
Beta-3 adrenergic receptor (T64A) genotyping allele frequencies between the 2 sample 
populations (HIV positive and HIV negative). The genotyping results for these 
polymorphisms are shown in table 3.5 across the 2 populations.  
 
The HIV positive population were further classified into subjects with and without 
lipoatrophy based on the self-assessment lipodystrophy questionnaire. Lipoatrophy was 
present in 34% (n=71) of the subjects. Zinn and co-workers (2013) in South Africa found 
the prevalence of HIV-associated lipodystrophy in their study to be 11.7%. Nearly 90% 
of those patients were on stavudine (d4T). HIV patients in the present study majority 
(65%) of the subjects had been on stavudine hence the prevalence of lipodystrophy was 
higher. 
 
Similar to the above finding, the frequency of ApoCIII C455T and T482C revealed no 
significant differences in the allele frequencies between the group with and without 
lipoatrophy. The difference in frequency of the T and A alleles in the β3-Adrenergic 
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receptor polymorphism between subject with and without lipoatrophy was not significant 
either. 
 
Perhaps of note in this study is the finding in the TNF alpha G308A allele frequency 
differences. The frequency of the variant allele -308A was significantly higher (0.25 vs. 
0.13; p<0.05) in subjects with lipoatrophy as compared to those without lipoatrophy. The 
result suggested that lipoatrophy was associated with the presence of the variant allele 
A at the TNF alpha 308 locus. Mahajan and coworkers (2014) showed a different finding 
in the Indian population, that the presence of the TNF-α SNPs especially, 238G/A 
promoter polymorphism was found to be associated with lipodystrophy. It was 
anticipated that the TNF-α SNP may be associated with HIV-1 lipodystrophy 
progression and could therefore be used as clinical prognostic marker to predict the 
development of HIV-1 associated lipodystrophy. The pathogenic mechanisms 
underlying HIV-1 lipodystrophy progression are unknown, but several studies suggest 
that TNF- α can alter the normal metabolic state and contribute to the progression of 
lipodystrophy (Mekinian et al., 2011). Again it is possible that ethnic difference may play 
a role in the different allelic distribution seen between different studies. 
 
HIV Treatment Results 
The results of patients with and without lipoatrophy were further classified into the 
treatment type the subjects were on. The treatment duration was also considered in this 
classification. The results indicated that a higher percentage (85%) of subjects with 
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lipoatrophy were on the 1st line treatment of HIV. There was also a significant difference 
in the treatment duration between subjects with and without lipoatrophy. This finding 
indicated that the longer subjects were on treatment the higher the possibility of 
developing lipoatrophy. This finding confirms what had been shown in the South African 
population by Innes and his co-workers (2012) that the overall time on ART, period on 
standard dose stavudine, increasing lamivudine exposure and cumulative efavirenz 
exposure were associated with visually obvious lipoatrophy. 
 
 
4.2 Conclusion 
The association of TNF-alpha (G308A) polymorphism with lipodystrophy in HIV positive 
patients receiving antiretroviral therapy was shown in this study. The presence of the 
variant allele of TNF-alpha (G308A) was significantly higher in subjects with lipoatrophy, 
however the lipid profile of the subjects with lipoatrophy was not affected by the 
presence of this variant allele. Ethnic differences might have contributed to lipoatrophy 
being associated with the variant allele of TNF-alpha 308 compared to other studies that 
found association with TNF-alpha 238.  
Furthermore, a higher percentage of subjects with lipoatrophy were on 1st line treatment 
of antiretroviral therapy (p=0.02) and had been on treatment for a longer duration. The 
presence of Stavudine in 1st line treatment may have contributed to patients developing 
of lipoatrophy. This correlation has been shown in other studies as well. 
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4.3 Limitations of the Study 
The 100 subjects used as controls for the study were assumed HIV negative. There 
were no actual tests performed to confirm that they were HIV negative. This was a 
cross-sectional study and no baseline data was available which meant that changes in 
anthropometric measurements since starting HAART could not be noted. 
The access to body imaging techniques is very limited and expensive in South Africa. 
Hence morphological differences between HIV positive with LDS and without LDS could 
not be compared. 
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Appendix A: Loading buffer and gel electrophoresis preparation 
 
 1X TBE was prepared by dissolving 10.8g Tris (hydroxymethylaminomethane) 
(Merck, Germany),5.5g boric acid (Merck, Germany) and 4ml of 0.5M EDTA 
(Sigma, Germany) in distilled water. The distilled water was added up to 1000 ml. 
0.5M EDTA (ethylene diaminetetraacetic acid) was prepared by dissolving 9.3g 
EDTA in 50ml distilled water and adjsted to pH 8.0.  
 2% (w/v) agarose solution was prepared by dissolving 1g agarose tablets in 50ml 
1X TBE (running buffer)and heating in a microwave for 1 minute.  
 5µl ethidium bromide was added. 
 Gel was prepared for electrophoresis using a gel comb & casting tray 
 The gel was allowed to set for 30min before electrophoresis 
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 Appendix B: Subject information sheet for participant group
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Appendix C: Informed consent form 
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Appendix D: Data collection form 
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Appendix E: Lipodystrophy assessment questionnaire 
 
 
100 
 
 
 
 
 
 
 
101 
 
 
 
 
102 
 
 
 
 
 
 
103 
 
 
 
 
104 
 
Appendix F: Ethics clearance 
 
 
 
 
 
 
